Stockreport

Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate

AptarGroup, Inc.  (ATR) 
Last aptargroup, inc. earnings: 4/30 05:04 pm Check Earnings Report
US:NYSE Investor Relations: investors.aptar.com
PDF The use of LuerVax® and Spray Divider™ support Aptar’s commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory [Read more]